These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36607902)

  • 21. Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes.
    Nowak M; Nowak W; Grzeszczak W
    Endokrynol Pol; 2022; 73(4):745-755. PubMed ID: 35593668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.
    Permana H; Yanto TA; Hariyanto TI
    Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide.
    Patoulias D; Papadopoulos C; Fragakis N; Doumas M
    Am J Cardiol; 2022 Oct; 181():139-140. PubMed ID: 35977865
    [No Abstract]   [Full Text] [Related]  

  • 24. Add-on value of tirzepatide versus semaglutide.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):377-378. PubMed ID: 35468323
    [No Abstract]   [Full Text] [Related]  

  • 25. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
    Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tirzepatide: A Systematic Update.
    Forzano I; Varzideh F; Avvisato R; Jankauskas SS; Mone P; Santulli G
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
    Kadowaki T; Chin R; Ozeki A; Imaoka T; Ogawa Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):634-644. PubMed ID: 35914542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tirzepatide Trial Demonstrates Substantial Weight Loss.
    Slomski A
    JAMA; 2022 Jul; 328(4):322. PubMed ID: 35881126
    [No Abstract]   [Full Text] [Related]  

  • 31. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ; Radermecker RP; Paquot N
    Rev Med Suisse; 2022 Aug; 18(792):1539-1544. PubMed ID: 36004653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In type 2 diabetes with increased CV risk, tirzepatide reduced HbA
    Singh M
    Ann Intern Med; 2022 Mar; 175(3):JC34. PubMed ID: 35226523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of medications to prevent type 2 diabetes.
    Buchanan TA; Xiang AH
    Curr Diab Rep; 2005 Aug; 5(4):237-9. PubMed ID: 16033670
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T; Bergenstal RM; Rodríguez A; Fernández Landó L; Bray R; Tong Z; Brown K
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):407-417. PubMed ID: 35468321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
    Wilson JM; Lin Y; Luo MJ; Considine G; Cox AL; Bowsman LM; Robins DA; Haupt A; Duffin KL; Ruotolo G
    Diabetes Obes Metab; 2022 Jan; 24(1):148-153. PubMed ID: 34542221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N; Takeuchi M; Oura T; Imaoka T; Seino Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):623-633. PubMed ID: 35914543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist.
    Tall Bull S; Nuffer W; Trujillo JM
    J Diabetes Complications; 2022 Dec; 36(12):108332. PubMed ID: 36375235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Early insulin treatment in type 2 diabetes--no].
    Nauck M
    Dtsch Med Wochenschr; 2013 May; 138(18):957. PubMed ID: 23613376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.